TABLE 4.
PointFinder predicted resistance compared with phenotypic drug susceptibility testing on the ReSeq data set when considering premature stop codons in katG, pncA, ethA, and gidB as resistance markers.
| Drug | Res | Sus | Spec. | Sens. | MCC |
| RMP | 771 | 2710 | 0.965 | 0.887 | 0.848 |
| INH | 1093 | 2420 | 0.929 | 0.909 | 0.823 |
| STM | 728 | 1239 | 0.847 | 0.839 | 0.674 |
| EMB | 466 | 3040 | 0.796 | 0.850 | 0.484 |
| PZA | 325 | 2993 | 0.935 | 0.612 | 0.502 |
| KAN | 76 | 617 | 0.989 | 0.776 | 0.814 |
| FLQ | 240 | 1175 | 0.956 | 0.679 | 0.664 |
| AMK | 107 | 866 | 0.785 | 0.766 | 0.386 |
| ETH | 50 | 175 | 0.829 | 0.800 | 0.564 |
| CAP | 116 | 1024 | 0.971 | 0.474 | 0.512 |
Green indicates an increase and Red a decrease in performance compared to the initial prediction in Table 2. Res, number of resistant strains determined by drug susceptibility testing; Sus, number of susceptible strains determined by drug susceptibility testing; Spec, specificity; Sens, sensitivity; MCC, Mathew Correlation Coefficient; RMP, Rifampicin; INH, Isoniazid; STM, Streptomycin; EMB, Ethambutol; PZA, Pyrazinamide; KAN, Kanamycin; FLQ, Fluoroquinolone; AMK, Amikacin; ETH, Ethionamide; CAP, Capreomycin.